Semax Amidate · Research brief

Semax: The Research Peptide Overview for Laboratory Use

Real Peptides Research TeamEditorial

Updated September 5, 202611 min read

51 WORDS

Short answer

Semax is a synthetic heptapeptide — the ACTH(4-7) fragment Met-Glu-His-Phe joined to a Pro-Gly-Pro tail — developed in Russia as a metabolically stabilized, non-corticotropic melanocortin analog. Research examines its effects on neurotrophin expression, cerebral ischemia models, learning and memory tasks, and stress physiology. It is supplied for laboratory research use only.

Key takeaways

Semax is a synthetic heptapeptide built from the ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro tail added to slow enzymatic degradation.
It is described in the literature as a melanocortin-derived, non-corticotropic peptide; reported mechanisms center on neurotrophin signaling (notably BDNF and NGF), transcriptional modulation, and metal-ion interactions.
Published work spans cerebral ischemia-reperfusion models, cognition and memory studies in rodents, stress physiology, and more recent Alzheimer's-model and copper-chelation investigations — much of it preclinical and preliminary.
Semax is not FDA-approved for any of the applications discussed here; material sold by Real Peptides is for laboratory research use only and not for human or veterinary use.
Lyophilized peptide is generally handled cold, protected from light and moisture, and reconstituted with an appropriate sterile diluent; solution stability is shorter than powder stability.
Supplier quality is judged on batch-specific third-party COAs, HPLC purity chromatograms, mass spectrometry identity confirmation, and traceable lot numbering.

What Semax Is and Where It Came From

Semax belongs to a family of short peptides derived from adrenocorticotropic hormone (ACTH). The parent molecule, ACTH, is a 39-amino-acid pituitary hormone, but decades of fragment work established that its behavioral and neurotrophic activities could be separated from its steroidogenic activity. The ACTH(4-10) region carried much of the neurotropic signal without driving cortisol release; ACTH(4-7) — Met-Glu-His-Phe — retained activity in a still shorter form.

The practical problem with such a fragment is survival time. Free tetrapeptides are cleaved rapidly by aminopeptidases and carboxypeptidases in plasma and tissue. Researchers at the Institute of Molecular Genetics and Moscow State University addressed this by appending the tripeptide Pro-Gly-Pro to the C-terminus. That proline-flanked tail sharply slows exopeptidase attack and, notably, is itself a biologically active peptide studied independently in the same literature. The resulting sequence — Met-Glu-His-Phe-Pro-Gly-Pro — is what the field calls Semax.

Because the melanocortin core is preserved but the corticotropic portion is not, Semax is repeatedly described in published work as non-hormonal in the endocrine sense: it does not act as an ACTH receptor agonist driving adrenal steroid output in the way the full hormone does. That distinction is central to how the compound is framed in research settings.

Semax, Semax amidate, and adamantyl variants

Several structural relatives circulate in research supply. The amidated form replaces the free C-terminal carboxyl group with a carboxamide, a common medicinal-chemistry modification intended to further resist carboxypeptidase cleavage and alter charge at physiological pH. N-adamantyl Semax (commonly sold as Adamax) attaches a bulky lipophilic adamantane cage, a modification generally explored for altered membrane interaction and duration. These are distinct chemical entities with distinct analytical signatures — a point that matters when reading a COA — and Real Peptides maintains separate comparison guides covering how each variant differs from base Semax.

Reported Mechanism of Action

No single receptor fully explains the profile reported for Semax, and honest summaries of the literature say so. What the published work describes is a convergence of several plausible mechanisms.

Neurotrophin induction

The most consistently reported mechanism is upregulation of neurotrophic factor signaling. Work published in Cellular and Molecular Neurobiology reported that Semax and Pro-Gly-Pro activate transcription of neurotrophins and their receptor genes following experimental cerebral ischemia in rats — with brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) pathways among those examined. This positions Semax less as a classical receptor agonist and more as a modulator that shifts gene expression toward trophic and survival programs.

Transcriptome-level modulation

Broader transcriptomic analysis published in Genes in 2020 examined ACTH(4-7)PGP effects after cerebral ischaemia-reperfusion in rats, reporting changes across pathways associated with inflammatory and immune response and vascular processes rather than a single narrow target. That study's framing — protective properties observed at the transcriptome level — captures how much of the mechanistic literature is now written: broad expression signatures rather than a lock-and-key receptor story.

Melanocortin receptor interaction

As a melanocortin fragment, interaction with melanocortin receptor subtypes expressed in brain tissue is a reasonable and frequently proposed mechanism. The evidence here is more inferential than definitive, and researchers should treat receptor-level claims about Semax as an open area rather than settled pharmacology.

Metal ion chemistry

A more recent line of investigation treats Semax as a copper-binding peptide. A 2025 paper in Bioinorganic Chemistry and Applications characterized Semax as a copper chelator and reported decreased Cu(II)-catalyzed reactive oxygen species production and reduced cytotoxicity of amyloid-β in that system, attributing the effect to metal ion stripping and redox silencing. The histidine residue in the sequence provides an obvious coordination site. Relatedly, earlier work in Doklady Biological Sciences reported that Semax prevented learning and memory impairment caused by heavy metals in an animal model — a finding that sits comfortably alongside the chelation chemistry.

What the Research Literature Examines

The published body of work on Semax is heavily preclinical, substantially Russian in origin, and organized around a handful of recurring themes. Evidence quality varies considerably by area; the summary below is deliberately hedged.

Cerebral ischemia and neuroprotection

This is the densest area. Rodent models of cerebral ischemia-reperfusion dominate, with endpoints including infarct-related tissue outcomes, neurotrophin and receptor gene transcription, and inflammatory gene expression. Clinical work in Russia has explored ischemic stroke contexts, where the compound has a registered status domestically — but that regulatory history is jurisdiction-specific and does not constitute approval elsewhere. Independent, large-scale, multicenter replication outside that region remains limited.

Cognition, learning, and memory

Rodent behavioral studies report effects on learning acquisition and memory retention, including the heavy-metal-challenge work noted above. A 2020 Doklady Biological Sciences paper applied a functional connectomic approach to studying Selank and Semax effects, examining network-level rather than single-region changes. Human cognitive-performance data are far thinner than the popular discussion suggests, and claims about attention or focus in healthy adults should be read as extrapolation from animal work, not as demonstrated clinical findings.

Neurodegeneration models

A 2025 paper in Acta Naturae assessed the potential of Semax and a derivative for correcting pathological impairments in an animal model of Alzheimer's disease. Combined with the copper-chelation work, this represents an emerging but early-stage direction. Evidence remains preliminary and model-dependent.

Stress physiology and peripheral effects

Work in Bulletin of Experimental Biology and Medicine examined Semax influence on the morphofunctional state of hepatocytes under chronic emotional and painful stress, and a separate paper in the same journal reported anticoagulation and antiplatelet effects under acute and chronic immobilization stress. These peripheral findings are a useful reminder that a peptide studied for central endpoints may show hematological and hepatic signals worth controlling for in study design.

Open topics with weak evidence

Questions circulating in research forums — including whether Semax affects hair growth or hair loss — are not well supported by the peer-reviewed record. Real Peptides maintains a dedicated article examining what the available data actually show on that question.

Laboratory Handling in General Terms

Semax is supplied as a lyophilized (freeze-dried) white powder in sealed vials. General peptide handling principles apply, and the specifics — calculators, step-by-step reconstitution walkthroughs, and error-avoidance guides — live in the child articles rather than here.

Storage of lyophilized powder: peptides of this class are typically kept refrigerated or frozen, sealed, protected from light, and shielded from atmospheric moisture. Repeated warming and cooling cycles that generate condensation inside a vial are a common and avoidable source of degradation.
Reconstitution: an appropriate sterile diluent is introduced slowly against the vial wall rather than directed onto the powder cake, and the vial is swirled rather than shaken. Vigorous agitation can shear peptide chains and generate foam.
Solution stability: once in solution, stability windows are substantially shorter than for dry powder. Solutions are generally kept cold, protected from light, and dated at the point of reconstitution.
Freeze-thaw: repeated freeze-thaw cycling of reconstituted material is broadly discouraged across peptide chemistry; aliquoting at first reconstitution reduces the problem.
Documentation: laboratory practice favors recording lot number, diluent identity, reconstitution date, and storage conditions alongside experimental data, so that anomalous results can be traced back to material handling.

Amidated and adamantyl variants may behave differently in solubility and solution stability from base Semax, and should not be assumed interchangeable in handling protocols.

Regulatory and Research-Use Status

Semax is not approved by the FDA for any of the applications discussed on this page. It has not completed the US regulatory pathway for any indication, and it is not a dietary supplement, a food ingredient, or a compounding-eligible substance in the United States. Material supplied by Real Peptides is intended for research use only — in vitro and laboratory investigation by qualified personnel — and is not for human consumption, veterinary use, diagnostic application, or therapeutic purposes of any kind.

Regulatory status differs by jurisdiction. The compound has a domestic registration history in Russia, which is often cited in online discussion but carries no weight in US regulatory terms. Anti-doping status is a separate question governed by the World Anti-Doping Agency's prohibited list and its handling of substances without major regulatory approval; researchers whose work intersects sport science should consult current WADA documentation directly, and Real Peptides maintains a dedicated explainer on that topic. Institutional researchers remain responsible for their own IRB, IACUC, biosafety, and import compliance obligations.

How Researchers Evaluate Supplier Quality

Peptide identity and purity are not visually verifiable. A white powder tells a researcher nothing. The following documentation standards separate credible suppliers from the rest.

Document	What it establishes	What to look for
HPLC chromatogram	Purity — proportion of target peptide versus impurities	A published trace, not just a stated percentage; a dominant single peak; visible baseline and retention time
Mass spectrometry	Identity — that the molecule is the intended sequence	Observed mass matching the theoretical mass for the specific variant (base, amidate, or adamantyl differ)
Third-party lab issue	Independence from the seller	Named external laboratory, report date, analyst or lab signature
Batch traceability	That the COA corresponds to the vial received	Lot number on the COA matching the lot on the vial label

A generic COA reused across every batch is a meaningful warning sign, as is a purity figure quoted without a chromatogram behind it. Real Peptides publishes COAs per batch for this reason: a document that cannot be tied to a specific lot cannot support reproducible research. Researchers should also confirm the COA describes the correct chemical entity — an amidated variant will not match the theoretical mass of base Semax, and a mismatch there is either a labeling error or a substitution.

Where the Open Questions Are

Semax is unusual among research peptides in having a long publication history and, simultaneously, large gaps. Several matter for study design.

Receptor pharmacology. The primary molecular target or targets are not definitively established. Melanocortin receptor involvement is proposed; direct binding characterization is thinner than the mechanistic narratives suggest.
Central nervous system access. How much intact peptide reaches brain tissue, by what route, and in what form is an active question — particularly given that the Pro-Gly-Pro tail is itself bioactive and its cleavage may contribute to observed effects.
Geographic concentration of evidence. Much of the foundational literature originates from a small number of research groups. Independent replication in other laboratories would strengthen confidence in the core findings considerably.
Human data. Early clinical work reports outcomes in stroke and cognitive contexts, but sample sizes, blinding, and reporting standards vary. Extrapolation to healthy-subject cognition is not supported by the current record.
Variant comparability. Whether amidated and adamantyl derivatives share the mechanistic profile of base Semax, or diverge meaningfully, is under-characterized. Most published work concerns the base sequence.
Long-duration exposure. Chronic-exposure data — including on the hematological and hepatic parameters flagged in the stress literature — remain limited.

For researchers building a protocol, these gaps are the interesting part. They also define the boundary of what can honestly be said about this compound today: a well-studied peptide with a coherent mechanistic hypothesis, a substantial preclinical record, and a clinical evidence base that has not yet caught up.

Research-grade Semax: Real Peptides supplies Semax for laboratory research with a published third-party Certificate of Analysis for every batch. Research use only.

Explore Semax research on Real Peptides

The articles below go deeper on the questions researchers ask most about Semax.

Reconstitution, storage & handling

Research questions

Legal & regulatory

Research timelines & mechanisms

Stacks & comparisons

Safety & side effects

Semax Amidate with Alcohol Safety — What Researchers Know

Buying & quality

References

Peer-reviewed sources on Semax indexed in PubMed, listed for research context. Real Peptides supplies Semax for laboratory research use only.

The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease. Acta naturae, 2025. PMID 41479572. doi:10.32607/actanaturae.27808
Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing. Bioinorganic chemistry and applications, 2025. PMID 40496623. doi:10.1155/bca/4226220
Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2020. PMID 32342318. doi:10.1134/S001249662001007X
Novel Insights into the Protective Properties of ACTH((4-7))PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes, 2020. PMID 32580520. doi:10.3390/genes11060681
Influence of ACTG(4-7)-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress. Bulletin of experimental biology and medicine, 2017. PMID 28577097. doi:10.1007/s10517-017-3748-4
Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2017. PMID 28702721. doi:10.1134/S0012496617030048
Semax prevents learning and memory inhibition by heavy metals. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2016. PMID 27411820. doi:10.1134/S0012496616030066
The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study. Journal of molecular neuroscience : MN, 2011. PMID 20617398. doi:10.1007/s12031-010-9421-2

Questions

Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-7) fragment of adrenocorticotropic hormone; the terminal Pro-Gly-Pro tripeptide was added to slow enzymatic degradation by exopeptidases. That Pro-Gly-Pro tail is itself studied as a bioactive peptide, which complicates attribution of observed effects to the intact heptapeptide alone.

No. Semax is derived from a short fragment of ACTH but lacks the regions responsible for corticotropic activity. Published work consistently describes it as non-corticotropic — meaning it is not characterized as driving adrenal steroid output the way the full 39-amino-acid hormone does. The fragment retains neurotropic properties associated with the melanocortin region while separating them from endocrine signaling.

No. Semax is not FDA-approved for any indication in the United States, and it is not a dietary supplement or a compounding-eligible substance. It carries a domestic registration history in Russia, which is frequently cited online but has no bearing on US regulatory status. Material supplied by Real Peptides is for laboratory research use only and not for human or veterinary use.

Base Semax has a free C-terminal carboxyl group. The amidate form replaces it with a carboxamide, a modification generally intended to increase resistance to carboxypeptidase cleavage. Adamax adds a bulky lipophilic adamantyl group. Each is a distinct chemical entity with a different theoretical mass, so a COA for one will not validate another. Most published research concerns the base sequence.

Published work reports that Semax and Pro-Gly-Pro activate transcription of neurotrophins and their receptor genes following experimental cerebral ischemia in rats, with BDNF and NGF pathways among those examined. Broader transcriptomic analysis has reported changes across inflammatory, immune, and vascular gene sets rather than a single narrow target. These findings are preclinical, and independent replication outside the originating research groups remains limited.

A credible certificate of analysis is batch-specific and issued by an independent laboratory. It should include an HPLC chromatogram showing purity rather than a bare percentage, mass spectrometry data confirming observed mass against the theoretical mass for the specific variant, the issuing lab's name and report date, and a lot number matching the vial label. Reused generic COAs cannot support reproducible research.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA